Resolving inflammation. Restarting repair.

EVolution Therapeutics is developing local mRNA-LNP therapies designed to restore the body’s natural ability to resolve inflammation and repair damaged tissue.

Our lead programme targets chronic non-healing wounds, where persistent inflammation prevents normal healing and creates a significant clinical and economic burden.

As a preclinical-stage biotech spin-out from Aston University, we are building a platform with potential beyond wounds, including inflammatory skin, pulmonary, cardiovascular and fibrotic disease.

Explore our science
for investors

A different approach to inflammatory disease

Inflammation is not the problem — unresolved inflammation is.

Many current treatments focus on suppressing inflammatory signals. EVolution Therapeutics is taking a more regenerative approach by delivering mRNA that encodes pro-resolving proteins directly to the site of disease.

Our aim is to shift chronic inflammation towards resolution, repair and restored tissue function.

A local RNA therapy designed to restart repair

Our local delivery platform combines:

mRNA-loaded lipid nanoparticles
to encode therapeutic pro-resolving proteins.

Hydrogel-based local delivery
to retain treatment at the site of inflammation.

Repair-focused biology
to support tissue regeneration rather than short-term symptom control.

Together, this creates a flexible therapeutic platform for diseases where inflammation fails to resolve.

Learn More

Lead programme: chronic non-healing wounds

patients with wounds managed by the NHS in 2017/18

estimated annual NHS wound management cost

%

of the global population is estimated to be affected by chronic wounds.

%

of people with diabetes are estimated to develop a diabetic foot ulcer during their lifetime.

Chronic wounds are a clear example of failed inflammatory resolution. They are difficult to treat, costly to manage and often rely on passive wound care approaches.

EVolution Therapeutics is developing an active therapeutic approach designed to promote healing from within the wound environment.

Our lead programme provides the first clinical path for the platform, with broader potential across inflammatory and fibrotic diseases.

The challenge extends beyond chronic wounds…

Unresolved inflammation drives tissue damage across disease

Pulmonary disease

Resolving inflammation to protect and repair lung tissue.

Neuroinflammation

Encouraging resolution of chronic inflammation within the nervous system.

Cardiovascular Disease

Promoting healthy vascular healing following inflammatory injury.

Fibrotic Disease

Preventing excessive scarring by promoting healthy resolution of inflammation.

Inflammatory eye conditions

Promoting resolution of ocular inflammation to support tissue repair, reduce scarring risk and help preserve vision.

Advancing towards translational development

  • Aston University spin-out based on long-standing research in inflammation resolution and tissue repair
  • Preclinical data showing accelerated wound healing in multiple in vivo models
  • Local mRNA-LNP hydrogel platform in development
  • Two patent applications submitted
  • Supported by leading clinical, scientific and industry advisors
Our Science

Learn about us...

Read about our Journey

About Us

Our Team

Meet our Experts

Our team brings together expertise in immunology, RNA delivery, nanoparticle formulation, wound healing and translational development.

As an Aston University spin-out, EVolution Therapeutics combines pioneering academic science with clinical and industry insight to advance local mRNA-LNP therapies designed to resolve inflammation and restart repair.

Dr. Sri Bellary

Clinical Consultant

Sri Bellary is a Senior NHS diabetes consultant and nationally recognised expert in complex diabetes complications. He has led innovative models of diabetes care and is Deputy Editor-in-Chief of Therapeutic Advances in Endocrinology & Metabolism.

Dr. Matt Vassey

Chief Operating Officer

Matt possesses over a decade of expertise as a business development and technology commercialisation specialist, with a background in fundraising, partnerships, and development of innovative technologies.

Dr. James Gavin

Co-Founder & CEO

With expertise in extracellular vesicles and nano-based therapeutics, Dr Gavin maintains a commercial and growth focus to drive the development of transformative treatments for inflammatory diseases.

Prof. Andrew Devitt

Co-Founder & CTO

With over 30 years of experience in the field of inflammatory cell biology, Andrew Devitt is a distinguished professor and Executive Dean of the School of Medicine, Pharmacy & Biosciences

Dr. Ivana Milic

Co-Founder & CSO

A highly experienced analytical chemist and lecturer in Biosciences at Aston University. Dr Milic possesses world-leading expertise in mass spectrometry for analyses of proteins and highly challenging lipid classes.

Liz Dainty

Chief Financial Officer

Elizabeth qualified as a chartered accountant at KPMG and has over 25 years of experience in both the commercial and charity sectors, holding pivotal fiscal and project management roles with numerous biotech start-ups.

Latest News & Events

Hear From The Team...